Transfer learning-trained convolutional neural networks identify novel MRI biomarkers of Alzheimer\u27s disease progression. by Li, Yi et al.
The Jackson Laboratory 
The Mouseion at the JAXlibrary 
Faculty Research 2021 Faculty Research 
5-14-2021 
Transfer learning-trained convolutional neural networks identify 






See next page for additional authors 
Follow this and additional works at: https://mouseion.jax.org/stfb2021 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by The Jackson Laboratory: The Mouseion at the JAXlibrary
Authors 
Yi Li, Annat Haber, Christoph Preuss, Cai John, Asli Uyar, Hongtian Stanley Yang, Benjamin A Logsdon, 
Vivek M. Philip, Radha Krishna Murthy Karuturi, Gregory W. Carter, and Alzheimer's Disease Neuroimaging 
Initative 
Received: 25 February 2020 Revised: 9 November 2020 Accepted: 2 December 2020 Published online: 17March 2021
DOI: 10.1002/dad2.12140
R E S E A RCH ART I C L E
Transfer learning-trained convolutional neural networks
identify novelMRI biomarkers of Alzheimer’s disease
progression
Yi Li1 Annat Haber1 Christoph Preuss2 Cai John1 Asli Uyar1
Hongtian Stanley Yang2 Benjamin A. Logsdon3 Vivek Philip2
R. KrishnaMurthy Karuturi1 GregoryW. Carter1,2 The Alzheimer’s Disease
Neuroimaging Initiative*
1 The Jackson Laboratory, Farmington,
Connecticut, USA
2 The Jackson Laboratory, Bar Harbor, Maine,
USA






Cai John, TheUniversity ofTennessee,
Knoxville, Tennessee,USA
*Dataused inpreparationof this article
wereobtained fromtheAlzheimer’sDis-
easeNeuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators
within theADNI contributed to thedesign
and implementationofADNIand/orprovided
databutdidnotparticipate in analysis orwrit-















Introduction:Genome-wide association studies (GWAS) for late onsetAlzheimer’s dis-
ease (AD)maymiss genetic variants relevant for delineating disease stageswhen using
clinically defined case/control as a phenotype due to its loose definition and hetero-
geneity.
Methods: We use a transfer learning technique to train three-dimensional convolu-
tional neural network (CNN) models based on structural magnetic resonance imaging
(MRI) from the screening stage in theAlzheimer’sDiseaseNeuroimaging Initiative con-
sortium to derive image features that reflect AD progression.
Results: CNN-derived image phenotypes are significantly associated with fasting
metabolites related to early lipid metabolic changes as well as insulin resistance and
with genetic variants mapped to candidate genes enriched for amyloid beta degrada-
tion, tau phosphorylation, calcium ion binding-dependent synaptic loss, APP-regulated
inflammation response, and insulin resistance.
Discussion: This is the first attempt to show that non-invasive MRI biomarkers are
linked toADprogression characteristics, reinforcing their use in earlyADdiagnosis and
monitoring.
KEYWORDS
Alzheimer’s disease, convolutional neural networks, deep learning, disease progression, imaging
phenotypes, machine learning, magnetic resonance imaging; transfer learning
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HIGHLIGHTS
∙ Novel non-invasive magnetic resonance imaging (MRI)
biomarkers of Alzheimer’s disease progression.
∙ Transfer learning.
∙ Deep convolutional neural networks.
1 BACKGROUND
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder
that slowly degrades memory and cognitive functions. It is neu-
ropathologically defined by intracellular neurofibrillary tangles and
aggregated amyloid beta (Aβ) plaques,1 both of which can currently
be estimated accurately only post mortem. The phenotype in current
case/control genome-wide association studies (GWAS) for late onset
AD (LOAD)2–4 are based largely on clinical assessments, in which
mild cognitive impairment (MCI) and AD are determined by designed
memory and cognitive tests and clinical observations. These criteria
fail to reflect early AD hallmark characteristics such as Aβ plaques and
neurofibrillary tangles and highlight advanced AD, leaving the MCI
category widely heterogeneous and poorly understood. Consequently,
current GWAS for LOAD usually exclude MCI and therefore may miss
critical genetic variants associated with early AD characteristics and
progression.
Non-invasive brain imaging modalities such as magnetic resonance
imaging (MRI) and positron emission tomography (PET) are promising
tools for monitoring AD progression and its diagnosis. Imaging pro-
vides precise quantitative phenotypes, and numerous methods have
been proposed for analyzing neuropathology with MRI.5–9 However,
the high dimensionality of these phenotypes makes it challenging to
extract concise and interpretable information. Summary measures for
pre-defined regions of interest (ROI) are suboptimal for predicting the
onset and progression of AD because they are derived independently
of AD status.
In this article, we make use of deep convolutional neural networks
(CNN)10–13 to simultaneously extract relevant features and classify
patients using (structural)MRI data from theAlzheimer’sDiseaseNeu-
roimaging Initiative (ADNI) consortium. Deep CNN have become the
state-of-the-art methods for image classification14 due to their abil-
ity to form translation invariant hierarchical image features. To miti-
gate the scarcity of images in the ADNI dataset, and accommodate the
high number of model parameters that need to be learned, we adopt
a transfer learning technique.15,16 This technique uses an indepen-
dent data-trained 3D CNN model17 that is then fine-tuned using our
dataset of 1381 images. This greatly augments our image dataset and
ensures the learned CNNmodel is more robust to overfitting. Because
our baseline MRI images were taken 3 years prior to clinical labeling
and provide holistic snapshots of brain states, our CNN-derived image
features reflect earlier and more specific AD characteristics than the
memoryand cognitive performance features used for assessingADand
RESEARCH INCONTEXT
1. Systematic review: Case/control genome-wide associa-
tion studies (GWAS) for late onset Alzheimer’s disease
(AD) may miss genetic variants relevant for delineat-
ing disease stages because the cases highlight advanced
AD and widely heterogeneous mild cognitive impairment
patients are usually excluded. More precise phenotypes
for AD are in demand.
2. Interpretation: Convolutional neural networks (CNN)
trained on structural magnetic resonance imaging (MRI)
and clinical labels integrated AD classification and image
feature extraction in one step; transfer learning–trained
CNNweremore robust to overfitting, yieldingmore accu-
rate image features that predict AD progression. CNN-
derived image phenotypes were significantly associated
with metabolites related to early lipid metabolic changes
and insulin resistance, and with genetic variants mapped
to candidate genes enriched for amyloid beta degrada-
tion, tau phosphorylation, calcium ion binding-dependent
synaptic loss, APP-regulated inflammation response, and
insulin resistance.
3. Future direction: Relating theMRI biomarkers to specific
regions in original MRI images that drive the AD classifi-
cation.
MCI. This is supported by the significant associations we find between
the CNN-derived phenotypes and early AD-related metabolites and
genes (Figure 1). To our knowledge, this is the first attempt to link non-
invasiveMRI biomarkers with AD progression characteristics.
2 METHODS
2.1 MRI and clinically labeled data from the
ADNI consortium
Data for this study were obtained from the ADNI database
(adni.loni.usc.edu). ADNI is a longitudinal study in which initial
imaging is followed by annual reimaging. MRI images taken at the
initial stage are later categorized into fourmajor classes based on their
follow-up status: control, AD, stable MCI subjects who maintain the
same disease status throughout the follow-up period, and progressive
MCI subjects who convert from MCI to AD sometime during the
follow-up period. MCI were counted as stable MCI only if they were
followed-up for at least 3 years in this study. The conversion and
follow-up timelines for the 526MCI patients are shown in Table S1B in
supporting information.
We downloaded 817 screening images from the ADNI-1 cohort,
104 ADNI-GO new participants, and 624 ADNI-2 new participants.
Because AD patients rarely convert back, we included 162 Year 1
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F IGURE 1 Graphic summary of the analytical approach. AMP-AD,
AcceleratingMedicines Partnership-Alzheimer’s Disease; APOE,
apolipoprotein E; CNN, convolutional neural network; GWAS,
genome-wide association studies; MRI, magnetic resonance imaging
and 95 Year 2 images from ADNI-1 patients who were diagnosed
as AD at screening, 155 of which also had MRIs at screening, total-
ing 1802 images (Table S1A). The adding of Year 1/2 AD images to
screening images was expected to help CNN more accurately rec-
ognize progression-related image features. However, there were no
duplicate subjects in the downstream metabolite and GWAS analy-
sis. Some subjects in ADNI-1 have two MRI scans from the same ses-
sion; we kept the one in the “Scaled_2″ directory as recommended
by ADNI MRI core team. We filtered out Year 1 to 2 AD MRIs with
the rank of 4 or -1 (based on downloaded MRIMPRANK.csv) and
ADNI-GO/2MRIs with the quality of 4 or none (based on downloaded
MAYOADIRL_MRI_IMAGEQC_12_08_15.csv). When there was more
than one MRI scan from the same session after filtering, we kept the
onewith thehighest quality or the latest timepointwhenqualitieswere
equal.
FreeSurfer18,19 software (-autorecon1 option) was applied to cor-
rect motions, normalize image intensities, and strip bone tissue, fol-
lowed by manual checking of sagittal slice 101 of each MRI image,
ensuring that the mean intensity of the white matter was around 110
and skull was stripped correctly (FreeSurfer suggestions). Inappropri-
ate skull stripping was rescued by running mri_watershed with dif-
ferent watershed thresholds. MRIs with incorrect mean intensity of
the white matter or inappropriate skull stripping after rescuing were
excluded. To investigate whether co-registration is necessary when
applying CNN to brain image analysis, we used the Talairach transfor-
mation calculated in FreeSurfer (-autorecon1) to obtainMNI305 atlas-
registeredMRIs.
Age, four cognitive scores (Mini-Mental State Examination [MMSE],
Clinical Dementia Rating-Sum of Boxes [CDR-SOB], Functional Activ-
ities Questionnaire [FAQ], Alzheimer’s Disease Assessment Scale
[ADAS]), and various image summary measures at screening as well as
sex, education level, apolipoprotein E (APOE) genotype, and ethnicity
were downloaded. The subjects used for training CNN had MRIs and
all selected covariates, with only one subject missing cognitive score
examination date at screening.Most of theMRIs had examination date
within 2months from that of cognitive scores (Table S1C). The distribu-
tions of age, sex, MMSE, and APOE genotype are shown in Table 1.
2.2 CNN and feature formation
CNN is a type of supervised multiple-layer neural network that adopts
learnable convolutional kernels to detect hierarchical image features.
Because the same kernel slides over the whole image, the detected
image features are translation invariant.20 To reinforce this, input
images are often augmented during CNN training via transformations
such as multiple scaling and cropping. A loss value at the last layer of
a CNN is computed in the forward pass and iteratively minimized by
back-propagating the loss to all hidden layers to update their weights
based on the stochastic gradient descent rule.21
The pre-trained 3D CNN model used for the transfer learning
adopted ResNext101 network structure, which consists of 101 lay-
ers, and was trained using 300,000 Kinetics video clips.22 Only the
parameters in the last few layers of ResNext101 were fine-tuned dur-
ing the training stage of our dataset. We added nodes to the second-
to-last layer in ResNext101 structure to accommodate covariates
(Figure S1 in supporting information). Our preliminary classification
results showed that progressive MCI was frequently predicted as AD
by the CNN model, suggesting that the CNN classification possibly
reclassified patients with pending diagnosis. We therefore trained our
CNNmodels with the target classes of controls, stable MCI, and broad
AD (AD and progressiveMCI).
To maximize the chance of obtaining an accurate CNN model,
we generated 10-fold sample splits. The three classes of subjects were
evenly divided into 10 folds in a class-wise fashion; for each sample
split, one fold was used as an independent test set, the remaining nine
foldswere randomly split into training andvalidation setswith the ratio
of 9:1. One CNNmodel was learned on the training and validation sets
in each of the 10 sample splits, and the one with the highest classifi-
cation accuracy on the (independent) test set was selected as the best
model for downstream analyses.
The second-to-last layer of our CNN was the only layer that pro-
vided input for the class probabilities at the last layer, and therefore
contained the features that are themostpredictiveof the classification.
This layer yielded 2048 image features in the adopted ResNext101
structure (Figure S1). Covariates entered CNN at this layer and their
effectswere passed forward to compute the loss at the last layer, which
waspropagatedbackward to all thehidden layers including the second-
to-last layer. Hence, when there are covariates in our CNN model,
the extracted image features are covariate adjusted. To reduce the
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TABLE 1 Demographic assessment and APOE ε4 genotype distribution in ADNI and AIBL data
ADNI data AIBL data
No. of APOE ε4 copies No. of APOE ε4 copies
No. of
subjects Age Male/female 0 1 2
No. of
subjects Age Male/female 0 1 2 MMSE
Control 373 74.3± 6 182/191 274 91 9 107 70.8± 7 51/56 76 30 1 29.1± 1.1
AD 251 74.8± 8 134/117 84 114 53 74 73.2± 8 29/45 23 37 14 20.3± 5.6
sMCI 424 73.1± 8 255/169 246 141 37 10 77.2± 7 8/2 5 4 1 28.0± 1.5
pMCI 230 73.9± 7 134/96 77 114 39 11 74.9± 6 7/4 1 6 4 26.3± 1.7
P-Value1 0.047 0.26 5.72× 10–30 0.28 0.26 4.51× 10–10 2.93× 10–16
P-Value2 0.72 0.64 3.21× 10–09 0.25 0.43 0.033 0.18
Notes: Age is presented in amean± standard deviation format.
ADNI, sMCI, and pMCIwere estimated until 3 years from screening (for CNN training); AIBL, sMCI, and pMCIwere estimated until 6 years from baseline (for
CNN evaluation).
P-value1: P value of comparing AD and controls.
P-value2: P value of comparing sMCI and pMCI.
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AIBL, Australian Imaging, Biomarker & Lifestyle Flagship Study
of Ageing; APOE, apolipoprotein E;MMSE,Mini-Mental State Examination; pMCI, progressiveMCI; sMCI, stableMCI.
number of image features for downstream analyses, we applied prin-
cipal component analysis (PCA)23 to the 2048 image features, used the
broken stick model24 to estimate the number of PCs needed, followed
by a L1-norm regularized regressionmodel (Lasso
25) to select themost
informative PCs for distinguishing stable and progressive MCIs. These
PCs are hereafter referred to asCNN-derived imagephenotypes. After
CNNwas trained, covariateswere not needed to obtain the image phe-
notypes, but needed for disease status predictions.
We generated two sets of CNN-derived phenotypes. For the first,
we trained a CNN model with age at screening, sex, education level,
MRI field strength indicator (1.5T or 3T), and ethnicity as covariates
(hereafter Image CNN). For the second set, we includedAPOE genotype
as an additional covariate, along with four APOE-correlated cognitive
scores at screening (hereafter Augmented CNNmodel).
To evaluate the performance of our CNN-derived image pheno-
types, we correlated them with metabolites and genetic variants. We
also compared themwith conventional image summarymeasures, cog-
nitive scores, and clinical labels. See supporting information for addi-
tional details.
2.3 AIBL MRIs as a validation dataset
We used MR images from the Australian Imaging, Biomarker &
Lifestyle Flagship Study of Ageing (AIBL) to evaluate the performance
of the trained CNNs. AIBL, designed similarly to ADNI, is a longitudi-
nal study that follows-up participants every 18 months until 6 years
from screening. All subjects were assumed to be White, a subset of
whoseMRIswere provided at theADNIwebsite.We selected 207 sub-
jects who had one MRI scan at baseline and either remained as con-
trols/MCI/AD for at least 3 years or converted to AD during the 6-
year follow-up. Therewere only 10 stableMCI and 11 progressiveMCI
among 207 subjects. The MRIs, 60 of which were of 1.5T magnetic
strength and 147 of 3T, went through the same pre-processing step
as ADNI MRIs. Participants’ characteristics were described in Dang
et al.26 and Ellis et al.27 Age, sex, APOE ε4 genotype, and MMSE are
summarized in Table 1 and used here as covariates. Education level and
cognitive scores of ADAS and FAQ, not available to our access, were
assigned values of zero to remove their effects in our CNNs. CDR was
available and used here instead of CDR-SOB. Youden’s J statistics24
was applied to the class probabilities of CNN to determine the pre-
dicted class category.
3 RESULTS
3.1 Deep 3D CNN models classify transition
from MCI to AD accurately
The confusionmatrices for the best CNNmodels on unregisteredMRIs
are shown in Table 2. The Augmented CNN yielded prediction accuracy
of 0.992 for broad AD, 0.986 for controls, and between 0.911 (1-year
follow-up) to 0.801 (the final visit) for progressive MCI. In compari-
son, the Image CNN achieved prediction accuracy of 0.913 for broad
AD, 0.906 for controls, and between 0.822 (1-year follow-up) to 0.69
(the final visit) for progressiveMCI. The Image CNN had lower power to
differentiate stableMCI from healthy controls. Bothmodels had lower
error rate of predicting stable MCI as broad AD with longer follow-up
period (0.409 to0.192 forAugmentedCNN, 0.376 to0.2 for ImageCNN),
implying that some of the stable MCI that were predicted by CNN as
broad AD converted to AD when tracked for longer than 3 years. We
also trained the two CNN models using co-registered MRIs. As shown
in Figure 2A and B, CNN performance on non-registered and regis-
teredMRIswas not significantly different, verifying that CNN is able to
learn translation-invariant image features. However, Image CNN with
the samestructurehadabiggerperformancedifferencebetween train-
ing and test samples on registered MRI than on non-registered MRI
(Figure2C), implying that ImageCNNmightbe somewhatoverfitting for
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TABLE 2 Confusionmatrix for CNN predictions
Image CNN (trainedwithoutAPOE genotype and cognitive
score as covariates)
Augmented CNN (trainedwithAPOE genotype and
cognitive score as covariates)
Clinical label Control StableMCI Broad AD Control StableMCI Broad AD
3Y_ctrl (373) 0.895 (334) 0.0107 (4) 0.0938 (35) 0.96 (358) 0.0268 (10) 0.0134 (5)
AD (482) 0.0851 (41) 0.00207 (1) 0.913 (440) 0 (0) 0.0083 (4) 0.992 (478)
1Y_sMCI (425) 0.442 (188) 0.181 (77) 0.376 (160) 0.231 (98) 0.36 (153) 0.409 (174)
2Y_sMCI (336) 0.518 (174) 0.226 (76) 0.256 (86) 0.277 (93) 0.435 (146) 0.289 (97)
3Y_sMCI (296) 0.551 (163) 0.24 (71) 0.209 (62) 0.297 (88) 0.476 (141) 0.226 (67)
4Y_sMCI (278) 0.558 (155) 0.241 (67) 0.201 (56) 0.317 (88) 0.478 (133) 0.205 (57)
5Y_sMCI (271) 0.561 (152) 0.232 (63) 0.207 (56) 0.325 (88) 0.48 (130) 0.196 (53)
final_sMCI (255) 0.557 (142) 0.243 (62) 0.2 (51) 0.318 (81) 0.49 (125) 0.192 (49)
1Y_pMCI (101) 0.178 (18) 0 (0) 0.822 (83) 0.0198 (2) 0.0693 (7) 0.911 (92)
2Y_pMCI (190) 0.195 (37) 0.00526 (1) 0.8 (152) 0.0368 (7) 0.0737 (14) 0.889 (169)
3Y_pMCI (230) 0.209 (48) 0.0087 (2) 0.783 (180) 0.0522 (12) 0.0826 (19) 0.865 (199)
4Y_pMCI (248) 0.226 (56) 0.0403 (10) 0.734 (182) 0.0484 (12) 0.109 (27) 0.843 (209)
5Y_pMCI (255) 0.231 (59) 0.0549 (14) 0.714 (182) 0.0471 (12) 0.118 (30) 0.835 (213)
final_pMCI (271) 0.255 (69) 0.0554 (15) 0.69 (187) 0.0701 (19) 0.129 (35) 0.801 (217)
Notes: Number of samples is given in parentheses. The fraction at each entry stands for the ratio of the number of CNN predictions belonging to the column
category to the number of samples belonging to the row (clinical) category. That pMCI or ADwere predicted as broad AD, and control/sMCI were predicted
as non broad AD can be viewed as correct predictions in a broad sense.
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; APOE, apolipoprotein E; CNN, convolutional neural network;
pMCI, progressiveMCI; sMCI, stableMCI.
registered MRI. This is probably because the transferred pre-trained
CNNwas trained onnon-registered images.Hence, all the downstream
analyses are based on non-registeredMRIs.
3.2 Trained CNNs applied to AIBL MRIs
CNNanalysiswas also informative in ourAIBL validationdataset, espe-
cially for Image CNN as the relevant cognitive data were not available
for Augmented CNN. Area under the curve (AUC) of distinguishing con-
trols from AD was 0.78 for Image CNN and 0.76 for Augmented CNN.
AUC of differentiating stable and progressive MCI were lower—0.61
and 0.6, respectively (Table S3 in supporting information)—probably
due to the smaller sample size (21 subjects total). The Augmented CNN
performed worse than the Image CNN, probably because ADAS, FAQ
and CDR-SOB were not available. Potential reasons for the reduced
AUC compared to ADNI analysis include (1) MRI acquisitions in ADNI
and AIBL used slightly different protocols and (2) some overfitting in
the trained CNN in spite of the transfer learning, as the trained CNN
was fitted to a North American population whereas AIBL data were
drawn fromAustralia.
3.3 Image phenotypes derived from 3D CNNs
Using Lasso,25 we selected principal components 1, 4, and 9 as infor-
mative phenotypes from Image CNNmodel (hereafter imageCNN.PC1,
imageCNN.PC4, imageCNN.PC9), explaining 0.257, 0.035, 0.019of the
variance of the 2048 CNN-derived image features, respectively. Only
PC 2 (hereafter augmentedCNN.PC2) was selected from Augmented
CNN model, explaining 0.064 of the variance of the 2048 image fea-
tures. Only imageCNN.PC4 and augmentedCNN.PC2 had a high cor-
relation coefficient of 0.72; all other pairwise correlations of PCs were
below 0.3.
3.4 Image phenotypes are associated with early
AD-related metabolites
Seven metabolites were found to be significantly (P < 0.05/55 =
0.0009) associated with the four CNN-derived phenotypes in the
ADNI-1 participants (Table S4 in supporting information), including
two phosphatidylcholines (PC) metabolites (PC ae C44:4 associated
with imageCNN.PC1, PC aa C32:3 with augmentedCNN.PC2), and
three sphingomyelin (SM) metabolites (SM C16:1, SM C18:0, and SM
C20:2, with augmentedCNN.PC2). These PC or SM metabolites were
previously found to be significantly associated with cerebrospinal fluid
(CSF) Aβ 1-42 and/or CSF tau in ADNI-1 cohort, either directly or
indirectly.28 Significant branched-chain amino acids included histidine
(with imageCNN.PC9) and isoleucine (with augmentedCNN.PC2), both
of which have been previously implicated in insulin resistance.28,29 We
need to caution the reader that the interpretationmaybeoverstatedas
the metabolite association was performed only in ADNI-1 participants
while image-derived phenotypes were obtained from ADNI-1/GO/2
participants.
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F IGURE 2 Average AUC (area under the receiver operating characteristic curve) of predicting stable and progressivemild cognitive
impairment (MCI) among 10 sample splits for six follow-up periods, comparing registered and non-registered images. A, Image CNNmodel on test
samples (with error bar). B, Augmented CNNmodel on test samples (with error bar). C, Comparison of average AUC between training and test
samples. CNN, convolutional neural network; pMCI, progressivemild cognitive impairment; sMCI, stable mild cognitive impairment
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3.5 GWAS using CNN-derived image phenotypes
The results for meta GWAS on imputed SNPs (see supporting infor-
mation) using the four CNN-derived image phenotypes are shown in
Table 3 and Table S5 in supporting information. QQ plots for all phe-
notypes show no obvious inflation of large P-values (> 1 × 10–4), with
λGC between 0.993 and 1.01, indicating that our association analyses
have accounted for population substructurewell (Figure S2 in support-
ing information).
Using imageCNN.PC1 as a phenotype, we obtained genome-
wide significant P-values (<5 × 10–8) for genetic variants at the
APOE/TOMM40 locus (Figure S2A). However, its QQ plot shows
no upward deviation from the diagonal line when single nucleotide
polymorphisms (SNPs) at the APOE/TOMM40 locus are excluded
(Figure S2B), suggesting that imageCNN.PC1 is not significantly asso-
ciated with any genetic variants outside APOE given the current
sample size. In contrast, using imageCNN.PC4, imageCNN.PC9, and
augmentedCNN.PC2 as phenotypes revealed no significant variants at
theAPOE/TOMM40 locus (P<1×10–5). TheirQQplots showmoderate
excess of lowP-values evenwhenSNPs at theAPOE/TOMM40 locus are
excluded (Figure S2C-2E), suggesting that these phenotypes are signif-
icantly associatedwith variants outsideAPOE given the current sample
size.
GWASbased on imageCNN.PC4 and imageCNN.PC9 identified 116
and 41 significant (P < 1 × 10–5) SNPs, respectively (Figure 3A), which
were mapped to 17 protein-coding genes (within ±15 kb) according to
FUMA.30 Identified SLC24A4 (rs12588868,P=9.07×10–6) is a known
AD gene;4 two genes, CACNA1C (rs11062078, P = 3.14 × 10–6) and
DYSF (rs34707417, P= 6.38× 10–6), were significantly enriched in the
Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD)
gene co-expression submodules (Figure S3 in supporting information).
The Gene Ontology (GO) annotations for the enriched submodules
include regulation of action potential and calcium-mediated signaling
for CACNA1C and regulation of endocytosis for DYSF (Table S7 in sup-
porting information). DYSF has been reported to be significantly asso-
ciated (P< 1× 10–4) with AD in an exome array association study.31
AugmentedCNN.PC2 identified 130 SNPs with P-values < 1 ×
10–5 (Figure 3B), which were mapped to 12 protein-coding genes
(within ±15 kb) according to FUMA. Two genes, CDH13 (rs67805160,
P = 4.26 × 10–6) and ENSA (rs112175941, P = 2.48 × 10–6) were sig-
nificantly enriched in AMP-AD gene co-expression submodules (Fig-
ure S3), whose GO annotations include calcium-dependent cell–cell
adhesion for CDH13, negative regulation of dephosphorylation, and
regulation of hormone/insulin secretion for ENSA (Table S8 in support-
ing information).
3.6 Candidate genes link image phenotypes
to AD-related functions
For Image CNN, three candidate genes (SLC24A4, CACNA1C, DYSF) are
related to the GO term of calcium ion binding, which may in turn play
a role in synaptic plasticity.32 NCAM2mediates synaptic adhesion, and
Aβ-dependent disruption of NCAM2 functions in the AD hippocampus
contributes to synapse loss.33 BRSK1 is the eQTL target gene of signif-
icant rs429498 in the AMP-AD RNA-Seq data, and mediates phospho-
rylation of tau.34 Therefore, we believe that Image CNNdetected image
patterns that are related to calcium ion binding, Aβ-mediated synaptic
loss, and tau phosphorylation.
ForAugmentedCNN,CDH13negatively regulates axongrowth35 and
LMF1 is required for maturation and transport of active lipoprotein
lipase (LPL).36 Previous studies have established that LPL is a novel Aβ-
binding protein promoting cellular uptake and subsequent degradation
of Aβ.37 ENSA is an inhibitor of protein phosphatase 2A (PP2A)38 that
regulates tau phosphorylation directly. ADCY3 loss-of-function vari-
ants increase the risk of obesity and type 2 diabetes.39 ZC3H12A (a.k.a.
MCPIP1), detected by both CNN models, is an APP-regulated inflam-
mation respondent in NT2 cells.40 All together, we believe that aug-
mentedCNN.PC2 represented both early (Aβ and tau related) and late
(insulin resistance/diabetes and inflammation response) AD character-
istics.
4 DISCUSSION
Augmented CNNmodel achieves higher prediction accuracy than Image
CNN model in the ADNI cohort. The high accuracy achieved by both
models, aswell as the four cognitive scores andAPOE genotype, for dis-
tinguishing stable and progressive MCI (Table S2 in supporting infor-
mation) implies that image, cognitive performance, and genetics have
complementary roles in disease status prediction.
ImageCNN.PC1 is the only CNN-derived phenotype to identify
genome-wide significant SNPs at the APOE locus because principal
components are uncorrelated with one another by definition and Aug-
mented CNN-derived image features were APOE-adjusted. This pheno-
type also had the highest power (AUC = 0.784) to predict the clini-
cal conversion of MCI to AD among all the phenotypes we considered
(Table S2), and the highest Pearson correlation with cognitive scores
(0.55withADAS and 0.52withCDR-SOB). However, itsQQplot shows
no excess of low P-values outside of the APOE locus. We therefore
believe that imageCNN.PC1 represents image features that aremainly
redundant with APOE genotype and cognitive performance.
The other three CNN-derived phenotypes show low correlations
with cognitive scores (<0.1) and have relatively low power to predict
the clinical conversion of MCI to AD (Table S2). This is probably due
to the conversion assessment being largely based on cognitive perfor-
mance in the first place. However, these phenotypes are associated
with early-stagemarkers of disease. For example, augmentedCNN.PC2
is significantly associated with the largest number of lipid metabolites
(three sphingomyelin and one phosphatidylcholines; Table S4), which
have been previously found significantly associated with CSF Aβ 1-42
and/or CSF tau.28 Furthermore, imageCNN.PC9 is significantly asso-
ciated with a metabolite of histidine, which has been implicated in
insulin resistance and p-tau.29,41 Their most significant SNPs map to
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F IGURE 3 Manhattan plots for (A) principal components (PCs) 1, 4, and 9 of the Image CNN-derived image features, and (B) PC 2 of the
Augmented CNN-derived image features. Gene names in red text are for imageCNN.PC1, those in blue text are for imageCNN.PC4,
imageCNN.PC9, and augmentedCNN.PC2
protein-coding genes that are enriched for diverse AD stages, rang-
ing from early Aβ, tau phosphorylation, and calcium ion binding-
related synaptic loss to late energy hypo-utilization and inflammation
response. Moreover, our CNN-derived phenotypes compare favorably
to other AD-related phenotypes (cognitive scores, image summary
measures, and clinical labels) in terms of metabolite association and
GWAS findings (Table S4 and S6 in supporting information). Although
theCNN-derived imagephenotypes couldbeexplained to somedegree
by a linear combination of image summary measures from ROIs—with
the highest explaining R2 of 0.358 for imageCNN.PC1 (Figure S4A in
supporting information), followed by the explaining R2 of 0.133 for
augmentedCNN.PC2 (Figure S4B) the majority of the image pheno-
types were unexplained by the ROIs, showing that the CNN-derived
image phenotypes provide novelMRI biomarkers.
These findings suggest that our CNN-derived image phenotypes
reflect AD progression better than other common phenotypes and
refine the genetic associations to key subprocesses for LOAD. Three
reasons may explain this. First, the transfer learning technique greatly
augments the ADNI image data,17 making the learned CNN mod-
els more robust to overfitting. Second, unlike our image phenotypes,
case/control LOAD GWAS often exclude MCI due to their uncertain
disease status and couldmisdiagnose healthy controls that developAD
later, yielding a less precise and less specific phenotype. Third, the cate-
gorical clinical labels aremore prone to errors due to the use of thresh-
olds than the continuous CNN-derived image phenotypes.42
Although we have applied FreeSurfer to the downloaded pre-
processed MRI images to correct motion and normalize image inten-
sities, we acknowledge that some confounding effects may not have
been accounted for, due to the different MRI acquisition parameters
adopted at different sites. This could also explain the lower prediction
power in the independent AIBLMRIs.
One direction for future studies is to explore CNN training strate-
gies that can better tolerate inaccurate target labels; another one is to
identify the regions in the originalMRI images that drive the CNN clas-
sification.
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